Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 11/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.36 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805069 | 0.92 | PIK3CG (0.40) | PIK3CGPIK3CDJAK2ROCK2NTRK1 | |
| SCHEMBL799155 | 0.90 | ROCK2 (0.39) | PIK3CGPIK3CDROCK2NTRK1PRKDC | |
| SCHEMBL799149 | 0.85 | LMNA (0.43) | PIK3CGPIK3CDROCK2HCAR1KDM4E | |
| SCHEMBL799301 | 0.84 | PIK3CG (0.46) | PIK3CGPIK3CDJAK2ROCK2NTRK1 | |
| SCHEMBL798720 | 0.80 | GCK (0.50) | PIK3CGPIK3CDJAK2ROCK2KDM4E | |
| SCHEMBL798945 | 0.79 | P2RY1 (0.40) | PIK3CGPIK3CDHCAR1KDM4ENPC1 | |
| SCHEMBL798946 | 0.79 | P2RY1 (0.40) | PIK3CGPIK3CDHCAR1KDM4ENPC1 | |
| SCHEMBL798713 | 0.79 | PIK3CG (0.43) | PIK3CGPIK3CDJAK2ROCK2NTRK1 | |
| SCHEMBL799157 | 0.79 | PIK3CG (0.48) | PIK3CGPIK3CDJAK2ROCK2KDM4E | |
| SCHEMBL798708 | 0.79 | PIK3CG (0.48) | PIK3CGPIK3CDJAK2NTRK1PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | PIK3CG 16/4885PIK3CD 10/4885JAK2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.